Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.51 |
| ▸ | SCD | O00767 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914141 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPK1USP2MEN1KMT2A | |
| SCHEMBL4922108 | 0.84 | MEN1 (0.53) | SMN1; SMN2MAPK1USP2MEN1KMT2A | |
| SCHEMBL4918176 | 0.84 | KDM4E (0.53) | SMN1; SMN2MAPK1USP2KDM4EHTT | |
| SCHEMBL2760778 | 0.83 | SCD (0.55) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL2720264 | 0.83 | SCD (0.55) | SMN1; SMN2MAPK1USP2KDM4EHTT | |
| SCHEMBL27687623 | 0.81 | MEN1 (0.47) | MEN1KMT2ASCDPOLB | |
| SCHEMBL2821695 | 0.81 | HCRTR1 (0.50) | SMN1; SMN2MAPK1USP2KDM4ESCD | |
| SCHEMBL4915391 | 0.81 | SCD (0.69) | SCD | |
| SCHEMBL1222253 | 0.79 | SCD (0.52) | SMN1; SMN2MAPK1USP2MEN1KMT2A | |
| SCHEMBL5816215 | 0.78 | HTT (0.48) | SMN1; SMN2MAPK1USP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071603-B2 | Contacting a source of hSCD with N-(2-Cyclopropyl-ethyl)-4-[4-(5-fluoro-2-trifluoromethyl-benzoyl)-piperazin-1-yl]-benzamide; elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2011-12-06 | — | — | US | disclosed |
| US-20080188488-A1 | Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-08-07 | — | — | US | disclosed |
| CN-101084207-A | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2007-12-05 | — | — | CN | disclosed |
| EP-1799664-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006034441-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188488-A1 | Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors | SCD, SCD5, FADS2 | SMN1; SMN2 1291/4885MAPK1 4164/4885USP2 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.